Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPaL-M versus BPaL-Lf for rifampicin-resistant tuberculosis in Vietnam
ISRCTN18086293Phase 4Completed
- Sponsor
- National Lung Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bedaquiline, pretomanid, linezolid, moxifloxacin and levofloxacin in Tuberculosis (TB) (2 arms), sponsored by National Lung Hospital. Primary endpoint: QTcF prolongation. Started Mar 2024; status: completed.
02
Drugs
bedaquilinepretomanidlinezolidmoxifloxacinlevofloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN18086293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18086293.